Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This study is designed as a phase Ib/II trial. The first part (phase Ib) is a dose escalation
design to explore the safety and assess the recommended phase 2 dose of Brentuximab Vedotin
in Hodgkin lymphoma patients treated with ICE regimen.
The second part, depending on the selected dose after the completion of phase Ib part of the
study, will further explore safety in addition to efficacy of the recommended dose of
Brentuximab Vedotin in a selected population of patients treated with ICE with Hodgkin
lymphoma.